These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 17263584)
1. Trends in the development and approval of monoclonal antibodies for viral infections. Reichert JM BioDrugs; 2007; 21(1):1-7. PubMed ID: 17263584 [TBL] [Abstract][Full Text] [Related]
2. [Antiviral humanized and human monoclonal antibodies]. Lashkevich VA Vopr Virusol; 2011; 56(5):4-8. PubMed ID: 22171470 [TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies against viruses and bacteria: a survey of patents. Xiao X; Dimitrov DS Recent Pat Antiinfect Drug Discov; 2007 Nov; 2(3):171-7. PubMed ID: 18221173 [TBL] [Abstract][Full Text] [Related]
4. Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond. Chaudhuri S; Symons JA; Deval J Antiviral Res; 2018 Jul; 155():76-88. PubMed ID: 29758235 [TBL] [Abstract][Full Text] [Related]
5. The growth and potential of human antiviral monoclonal antibody therapeutics. Marasco WA; Sui J Nat Biotechnol; 2007 Dec; 25(12):1421-34. PubMed ID: 18066039 [TBL] [Abstract][Full Text] [Related]
6. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. Boivin G; Caouette G; Frenette L; Carbonneau J; Ouakki M; De Serres G J Clin Virol; 2008 May; 42(1):52-7. PubMed ID: 18164233 [TBL] [Abstract][Full Text] [Related]
9. A molecular perspective for the development of antibodies against the human respiratory syncytial virus. Loaiza RA; Ramírez RA; Sepúlveda-Alfaro J; Ramírez MA; Andrade CA; Soto JA; González PA; Bueno SM; Kalergis AM Antiviral Res; 2024 Feb; 222():105783. PubMed ID: 38145755 [TBL] [Abstract][Full Text] [Related]
10. Palivizumab: where to from here? Georgescu G; Chemaly RF Expert Opin Biol Ther; 2009 Jan; 9(1):139-47. PubMed ID: 19063700 [TBL] [Abstract][Full Text] [Related]
11. [Antiviral therapy: from influenza to Pfeiffer's disease]. Salzberger B Internist (Berl); 2006 Dec; 47(12):1245-50. PubMed ID: 17009040 [TBL] [Abstract][Full Text] [Related]
12. What clinicians need to know about antiviral drugs and viral resistance. Hodinka RL Infect Dis Clin North Am; 1997 Dec; 11(4):945-67. PubMed ID: 9421709 [TBL] [Abstract][Full Text] [Related]
13. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Mejías A; Chávez-Bueno S; Ríos AM; Aten MF; Raynor B; Peromingo E; Soni P; Olsen KD; Kiener PA; Gómez AM; Jafri HS; Ramilo O Antimicrob Agents Chemother; 2005 Nov; 49(11):4700-7. PubMed ID: 16251314 [TBL] [Abstract][Full Text] [Related]
16. An overview on different classes of viral entry and respiratory syncitial virus (RSV) fusion inhibitors. Murineddu G; Murruzzu C; Pinna GA Curr Med Chem; 2010; 17(11):1067-91. PubMed ID: 20156158 [TBL] [Abstract][Full Text] [Related]
17. Palivizumab in the prevention of respiratory syncytial virus disease. Krilov LR Expert Opin Biol Ther; 2002 Oct; 2(7):763-9. PubMed ID: 12387675 [TBL] [Abstract][Full Text] [Related]